Natal
Biologically youngest MSCs available
99.9%
Post-thaw viability
Ethical
Post-birth collection, no fetal tissue
Quality
Scalable to commercial supply
Platform, not pipeline.
Alvion Bio is a platform company. We do not develop drugs or run clinical trials. We own the foundational cell technology that makes next-generation immune therapies possible, and we license it to the companies that do.
Our Revalyxis™ platform sources, isolates, expands and supplies amniotic mesenchymal stem cells (AMSCs) to pharmaceutical and biotech partners worldwide. One platform. Multiple partners. Compounding value.
Biologically Younger
Captured at birth, before the cellular ageing and damage accumulation that degrades adult stem cell function. Higher proliferative capacity and stronger immunomodulatory signalling than bone marrow or adipose-derived alternatives.
Ethically Sourced
Collected from amniotic fluid during consented caesarean deliveries. No fetal tissue. No invasive procedures. A post-birth source that eliminates the ethical constraints limiting other cell types.
Consistently Scalable
Proprietary isolation and expansion protocols deliver batch-to-batch consistency at commercial scale. GMP-compatible manufacturing designed for global pharmaceutical supply chains.
Seeing a new class of stem cells where others saw medical waste.
A small team of researchers in Malmö–Lund asked a question that changed their trajectory: why is modern cell therapy built on ageing, inconsistent adult stem cells, while the most pristine cells are routinely discarded after birth?
By developing an ethical, non-invasive method to collect and process post-birth amniotic fluid from standard caesarean deliveries, they unlocked access to natal mesenchymal stem cells in their earliest, most potent developmental state.
From that insight, Alvion Bio was founded not as a drug developer, but as the company that builds the cellular foundation on which the next generation of immune medicines will be made.